ArticleAnnals of medicine and surgery (2012)2026
Acute pancreatitis following semaglutide therapy: a case report.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute pancreatitis (AP) is a potentially life-threatening condition that can result from various aetiologies. While gallstones and alcohol consumption are the most common causes, medications can also induce AP. In the absence of a clear cause, drug-induced acute pancreatitis (DIAP) may pose challenges for clinicians. This is especially true when addressing unusual and rare causes such as glucagon-like peptide-1 receptor agonists. Case Presentation: A 41-year-old Saudi man was admitted to the hospital with epigastric pain after receiving subcutaneous semaglutide for weight loss. Laboratory test results revealed AP. Conclusions: In conclusion, semaglutide-induced acute pancreatitis is a rare but serious adverse effect. Clinicians should be aware of this potential adverse effect, particularly in patients without a history of diabetes mellitus who are using the drug for weight loss. Early recognition and discontinuation of the drug are crucial for the management of this condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.